The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Open accessAbstract
This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes. The age of symptom onset was earlier in APOE4 homozygotes at 65.1, with a narrower 95% prediction interval than APOE3 homozygotes. The predictability of symptom onset and the sequence of biomarker changes in APOE4 homozygotes mirrored those in autosomal dominant AD and Down syndrome. However, in the dementia stage, there were no differences in amyloid or tau positron emission tomography across haplotypes, despite earlier clinical and biomarker changes. The study concludes that APOE4 homozygotes represent a genetic form of AD, suggesting the need for individualized prevention strategies, clinical trials and treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“APOE is a lipoprotein involved in the transport of cholesterol and phospholipids between cells, and allelic variation in the APOE gene is a strong genetic risk factor for AD [16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The isoform variation of the protein is associated with an increased risk of developing AD in the general population [11, 16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Although APOEε4 homozygosity may approach 100% penetrance for Aβ deposition in the brain16, even for white or East Asian people, being homozygous for APOEε4 is not synonymous with developing AD dementia”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“APOE is a lipoprotein involved in the transport of cholesterol and phospholipids between cells, and allelic variation in the APOE gene is a strong genetic risk factor for AD [16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Self-citationPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationLaMontagne, P. J., Benzinger, T. L., Morris, J. C., Keefe, S., Hornbeck, R., Xiong, C., Grant, E., Hassenstab, J., Moulder, K., Vlassenko, A. G., et al. (2019) · medRxiv · doi:10.1101/2019.12.13.19014902 · Cited by 779
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 778
Self-citationAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.10.006 · Cited by 523
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
(2012) · New England Journal of Medicine · doi:10.1056/nejmx120056 · Cited by 385
The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database.
Beekly, D. L., Ramos, E. M., van Belle, G., Deitrich, W. D., Clark, A. D., Jacka, M. E., & Kukull, W. A. (2004) · PubMed · Cited by 371
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Self-citationFortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Altuna, M., Pegueroles, J., Montal, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30689-9 · Cited by 340
Self-citationAPOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
Belloy, M. E., Andrews, S. J., Le Guen, Y., Cuccaro, M., Farrer, L. A., Napolioni, V., & Greicius, M. D. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3599 · Cited by 320
van der Lee, S. J., Wolters, F. J., Ikram, M. K., Albert Hofman, D., Ikram, M. A., Amin, N., & van Duijn, C. M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30053-x · Cited by 317
La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
Iulita, M. F., Garzón Chavez, D., Klitgaard Christensen, M., Valle Tamayo, N., Plana-Ripoll, O., Rasmussen, S. A., Roqué Figuls, M., Alcolea, D., Videla, L., Barroeta, I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12910 · Cited by 195
Self-citationMolinuevo, J. L., Gramunt, N., Gispert, J. D., Fauria, K., Esteller, M., Minguillón, C., Sánchez‐Benavides, G., Huesa, G., Morán, S., Dal‐Ré, R., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.02.003 · Cited by 181
Self-citationMulti-method investigation of factors influencing amyloid onset and impairment in three cohorts
Betthauser, T. J., Bilgel, M., Koscik, R. L., Jedynak, B., An, Y., Kellett, K. A., Moghekar, A., Jonaitis, E. M., Stone, C. K., Engelman, C. D., et al. (2022) · Brain · doi:10.1093/brain/awac213 · Cited by 133
Self-citationPrevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis
Jansen, W., Ossenkoppele, R., Knol, D., Tijms, B., Scheltens, P., Fr, V., Visser, P. J., Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., et al. (2015) · Archive ouverte UNIGE (University of Geneva) · Cited by 94
Self-citationTherriault, J., Pascoal, T. A., Benedet, A. L., Tissot, C., Savard, M., Chamoun, M., Lussier, F., Kang, M. S., Berzgin, G., Wang, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011416 · Cited by 91
Mehta, R. I., & Schneider, J. A. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000912 · Cited by 87
Sadikki, H., Fayossé, A., Cognat, E., Sabia, S., Engelborghs, S., Wallon, D., Alexopoulos, P., Blennow, K., Zetterberg, H., Parnetti, L., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1003289 · Cited by 87
Jack, C. R., Therneau, T. M., Lundt, E. S., Wiste, H. J., Mielke, M. M., Knopman, D. S., Graff‐Radford, J., Lowe, V. J., Vemuri, P., Schwarz, C. G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac017 · Cited by 59
Ghisays, V., Goradia, D. D., Protas, H. D., Bauer, R. J., III, Devadas, V., Tariot, P. N., Lowe, V. J., Knopman, D. S., Petersen, R. C., Jack, C. R., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.08.195 · Cited by 35
Snellman, A., Ekblad, L. L., Tuisku, J., Koivumäki, M., Ashton, N. J., Lantero‐Rodriguez, J., Karikari, T. K., Helin, S., Bucci, M., Löyttyniemi, E., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01209-6 · Cited by 31
Lessons from Down syndrome and autosomal dominant Alzheimer's disease
Fortea, J., Quiroz, Y. T., & Ryan, N. S. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00437-9 · Cited by 10
Self-citation
Research works printed but not linked: 1
- Johnson, S. C. et al. The Wisconsin Registry for Alzheimer’s Prevention: a review of findings and current directions. Alzheimer’s Dement.: Diagnosis, Assess. Dis. Monit. 10, 130–142 (2018).
Cited by
Sorted by citations
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Lifetime risk and projected burden of dementia
Fang, M., Hu, J., Weiss, J., Knopman, D. S., Albert, M., Windham, B. G., Walker, K. A., Sharrett, A. R., Gottesman, R. F., Lutsey, P. L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03340-9 · Cited by 153
The Glutamate/ GABA ‐Glutamine Cycle: Insights, Updates, and Advances
Andersen, J. V. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70029 · Cited by 170
Ossenkoppele, R., Coomans, E. M., Apostolova, L. G., Baker, S. L., Barthel, H., Beach, T. G., Benzinger, T. L. S., Betthauser, T. J., Bischof, G. N., Bottlaender, M., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02000-6 · Cited by 60
Self-citation
Metadata
- Authors
- Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., Sperling, R., Bejanin, A., Lleó, A., & Montal, V.
- Affiliations
- Hospital de Sant Pau (ES)
- Universitat Pompeu Fabra (ES)
- University of Wisconsin–Madison (US)
- Brigham and Women's Hospital (US)
- Barcelona Supercomputing Center (ES)
- Corresponding author
- Fortea, Juan
- Montal, Víctor
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-05
- Volume
- 30
- Issue
- 5
- Pages
- 1284-1291
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC13310155
- OpenAlex
- W4396673676
- Cited by
- 369
- References
- 32
- Citations by year
- 2026: 110 · 2025: 191 · 2024: 67
- FWCI
- 104.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-06-17)
- Open access
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (U54HD090256, P01AG036694 and P50AG005134, R21 AG056974, R01 AG027161, S10 OD025245, UF1AG051216, P50 AG033514, and P30 AG062715, UL1 TR002373, P30 AG062715, R01 AG061566, R01 AG054059, R01 AG037639)
- Alzheimer's Association (AARG-22-923680)
- European Commission (948677 and 847648, H2020-SC1-BHC-2018-2020, Grant 2021)
- Generalitat de Catalunya (SLT006/17/00119, SLT002/16/00408)
- Ministerio de Economía y Competitividad (PI22/00307, PI20/01330, PI20/01473, PI18/00435, PI22/00456)
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona (LCF/PR/GN17/50300004)
- National Institutes of Health (5u01ag024904-10, 1s10od025245-01, UL1TR002373)
- National Institute on Aging (U01-AG-024904, R01AG081394, UF1AG051216, RF1AG056850, R61AG066543, R01AG037639, R01AG063689, P50AG033514, RF1AG061566, P50AG005134, R21AG056974, R01AG021155, R01AG027161, U24AG057437, P01AG036694, R01AG054059, P30AG062715, U24AG072122)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090256)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, APOE3, amyloid PET, cerebrospinal fluid amyloid, tau PET, symptom onset age, disease progression, autosomal dominant Alzheimer's disease, Down syndrome, penetrance, dementia stages
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Apolipoproteins E, Female, Homozygote, Humans, Male, Middle Aged, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Age of Onset, Positron-Emission Tomography, Apolipoprotein E3, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
